Navigation

Gastric cancer (HER2-positive metastatic) - trastuzumab

Trastuzumab for the treatment of HER2 positive advanced gastric cancer

Status: History
Expected date of issue: November 2010
Referral date: March 2009
Process: STA
Notes:

Cancer reform strategy Batch 5

Topic area:
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Joanne Holden
Communications manager: Alice Law
Project manager: Lori Farrar
Assessment Group / Evidence Review Group: NHS Centre for Reviews and Dissemination and Centre for Health Economics
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 1 March 2010
1st appraisal committee meeting: 09 June 2010
2nd appraisal committee meeting 11 August 2010
Top


 

Consultees and commentators

Consultees

 

Commentators (no right of appeal)

 

Manufacturers/sponsors

  • Roche Products (trastuzumab)

Patient/carer groups

  • None

Professional groups

  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • Welsh Assembly Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturers

  • Bristol-Myers Squibb (cisplatin)
  • Roche Products (capecitabine)

Relevant research groups

  • None

Evidence Review Group

  • National Institute for Health Research Health Technology Assessment Programme
  • NHS Centre for Reviews & Dissemination and Centre for Health Economics -York

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
19 November 2009 Following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late January 2010. The deadline for submissions is expected in approximately early April 2010.
13 August 2009 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late January 2010. The deadline for submissions is expected in approximately early April 2010.
Top


 

Key documents

This page was last updated: 24 November 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.